AbbVie has a deep heritage in oncology research and the technology and approaches we are taking to advance cancer treatment are becoming foundational to the next generation of cancer treatment. We research, validate, and target specific molecular pathways, allowing us to discover and develop innovative cancer therapies that aim to disrupt the natural progression of cancer cells. Our efforts combine a deep understanding of how cancer works with state-of-the-art technologies to deliver smarter solutions faster to the oncology community.
AbbVie’s research and development in oncology is focused on discovering novel pathways and targets with the goal of controlling and regulating cancer cells in various forms of both liquid and solid tumors. But we know it’s more than just the best science. AbbVie recognizes we also need to expedite the clinical development process, including clinical trial designs, if we are going to address the significant unmet medical needs in oncology.
AbbVie is currently evaluating 13 compounds in more than 190 active clinical trials in various settings around the world as potential treatment options for 19 different types of cancer. We have three world-class oncology research and development facilities focused on delivering breakthrough new approaches in the fight against cancer.